TABLE 4.
Summary of subject demographic and clinical characteristics
| AFM | UFM | OC | |
|---|---|---|---|
| No. Subjects | 77 | 42 | 68 |
| No. Females (%) | 42 (54) | 27 (64) | 37 (54) |
| Mean Age (range) | 33 (0–75) | 44 (3–87) | 43 (0–81) |
| No. Pediatric <18 (%) | 20 (26) | 5 (12) | 6 (9) |
| Median bleeding score (range) | 1 (0–46) | 1 (0–9) | 1 (0–11) |
| No. Blood Group O (%)a | 44 (59%) | 9 (20%) | 30 (44%) |
| Mean FVIII (range)b | 56 (2–149) | 122 (71–200) | 86 (21–174) |
| Mean VWF:Ag (range)b | 27 (<1–81) | 89 (56–211) | 48 (12–155) |
| Mean VWF:RCo (range)b | 31 (<1–83) | 88 (57–201) | 47 (13–160) |
Note: Central Factor VIII activity (FVIII), VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo) and bleeding score obtained at study entry.
Abbreviations: AFM, affected family members; OC, obligate carriers; UFM, unaffected family members (UFM).
a
Subjects who were too young or unable to obtain blood type were excluded.
b
Eight type 3 treated subjects were excluded from the mean and range determinations.